“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
TOKYO and CAMBRIDGE, Mass., July 11, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer’s disease (AD…
Read More
0
